Contributions
Abstract: PB2223
Type: Publication Only
Background
Thrombophilias are genetic conditions that increase the risk of thromboembolic disease. The use of anticoagulant therapy during pregnancy is challenging because of the potential for both fetal and maternal complications. The most common complication is venous thromboembolism.
Aims
This study is conducted in order to assess the importance of treatment during pregnancy for women with hereditary thrombophilia, the risks of not treating the disease or treating incorrectly.
Methods
This study includes a total of 207 women, from which 83% were treated with low molecular weight heparin and Aspirin during pregnancy regardless if it was their first pregnancy or not and the rest 17% remained untreated during pregnancy. The success of the treatment is based on the completion of the pregnancy and the good health of the fetus.
Results
A total of 207 women were included into the study, 172 were treated with low molecular weight heparin and Aspirin while 35 were treated with just Aspirin. Out of 172 patients in the low molecular weight heparin group 155 managed to give birth which accounts for a 90% success rate with a reported case of fetal growth restriction and 2 cases of abruption while the remaining 17 women which represent the 10% of the treated patients were unsuccessful in completing their pregnancy with 14 women presenting pregnancy loss on the first trimester and 2 having late fetal loss, only one case of preeclampsia was recorded. Out of the 35 women who did not receive treatment with low molecular weight heparin and only with Aspirin, 21 managed to complete their pregnancies representing the 60% out of which 2 cases presented with Abruption and 4 cases with fetal growth restriction, out of the 14 women who represent the 40% who were unsuccessful in completing their pregnancies 7 cases were recorded during the first trimester while 3 more had late fetal loss and 4 cases of preeclampsia.
Conclusion
Women treated for thrombophilia had a lower percentage of fetal loss than their no treatment group counterparts. There is an urgent need for appropriate guidelines for these patients in our medical center.
Session topic: 34. Thrombosis and vascular biology
Abstract: PB2223
Type: Publication Only
Background
Thrombophilias are genetic conditions that increase the risk of thromboembolic disease. The use of anticoagulant therapy during pregnancy is challenging because of the potential for both fetal and maternal complications. The most common complication is venous thromboembolism.
Aims
This study is conducted in order to assess the importance of treatment during pregnancy for women with hereditary thrombophilia, the risks of not treating the disease or treating incorrectly.
Methods
This study includes a total of 207 women, from which 83% were treated with low molecular weight heparin and Aspirin during pregnancy regardless if it was their first pregnancy or not and the rest 17% remained untreated during pregnancy. The success of the treatment is based on the completion of the pregnancy and the good health of the fetus.
Results
A total of 207 women were included into the study, 172 were treated with low molecular weight heparin and Aspirin while 35 were treated with just Aspirin. Out of 172 patients in the low molecular weight heparin group 155 managed to give birth which accounts for a 90% success rate with a reported case of fetal growth restriction and 2 cases of abruption while the remaining 17 women which represent the 10% of the treated patients were unsuccessful in completing their pregnancy with 14 women presenting pregnancy loss on the first trimester and 2 having late fetal loss, only one case of preeclampsia was recorded. Out of the 35 women who did not receive treatment with low molecular weight heparin and only with Aspirin, 21 managed to complete their pregnancies representing the 60% out of which 2 cases presented with Abruption and 4 cases with fetal growth restriction, out of the 14 women who represent the 40% who were unsuccessful in completing their pregnancies 7 cases were recorded during the first trimester while 3 more had late fetal loss and 4 cases of preeclampsia.
Conclusion
Women treated for thrombophilia had a lower percentage of fetal loss than their no treatment group counterparts. There is an urgent need for appropriate guidelines for these patients in our medical center.
Session topic: 34. Thrombosis and vascular biology